Rigel pharmaceuticals inc (RIGL)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities
Net income (loss)

-28,053

-66,894

-46,466

-58,742

-63,693

-70,480

-99,579

-93,473

-87,063

-77,992

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-50,735

-

-61,049

-75,319

-86,798

-90,908

-85,497

-88,379

-85,756

-89,027

-97,638

-99,270

-101,240

-98,840

-99,155

-91,630

-88,366

-85,973

0

0

0

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation expense

8,186

9,115

9,761

10,658

9,117

7,704

8,706

6,584

6,572

5,987

5,594

5,936

6,850

7,333

6,292

6,892

6,787

7,403

8,989

9,254

9,477

9,787

8,139

8,122

7,737

7,166

8,866

10,048

11,312

12,617

12,395

12,240

12,429

13,168

0

0

0

Gain on disposal of assets

-

-

-

-

-

-

-

-

-

732

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sublease

-

-

-

-

-

-

-

-

-

495

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

690

683

666

659

645

594

544

497

452

465

495

597

743

941

1,136

1,209

1,328

1,439

1,608

1,895

2,139

2,359

2,503

2,573

2,578

2,592

2,577

2,568

2,550

2,433

2,323

2,194

2,060

1,955

0

0

0

Non-cash operating lease expense

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net amortization and accretion of discount on short-term investments and term loan

929

1,073

1,142

1,062

914

766

693

560

451

350

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable, net

4,046

6,034

0

0

0

-

-

-

-

-

-

-

-

-203

-163

-255

89

-5,547

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

405

366

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and other current assets

4,472

5,673

3,917

2,111

2,022

1,797

93

24

900

197

140

-372

-396

-1,097

-375

632

518

917

396

-280

-1,183

-722

-860

-1,425

-511

-1,867

-603

-799

180

1,624

-176

262

-111

-38

0

0

0

Other assets

-68

-39

43

35

459

-68

-185

-195

-630

-130

-133

-139

-154

-167

-237

-179

-177

-159

-377

-440

-423

-439

-172

-183

-217

-231

-240

-231

-231

-232

-224

-255

-358

-244

0

0

0

Accounts payable

1,028

-2,239

20

435

-964

3,755

448

1,267

945

-2,947

655

555

-1,246

2,800

829

404

1,288

1,150

-329

-800

-21

-2,290

-7

-225

-981

2,206

-363

209

216

141

113

451

650

153

0

0

0

Accrued compensation

1,075

-1,133

-433

423

-314

2,893

2,756

1,781

2,125

2,974

191

540

-531

-2,166

191

-881

-562

3,419

725

828

1,239

-17

762

469

-796

-3,926

-2,525

-970

186

-496

882

321

552

2,460

0

0

0

Accrued research and development

-304

-803

-170

-47

1,127

1,735

1,393

323

-358

-853

-3,278

-1,531

-1,009

928

2,487

2,409

2,791

960

2,173

1,523

2,136

2,405

347

749

237

-536

409

-921

869

57

0

0

0

-

-

-

-

Other accrued liabilities

1,689

3,122

3,051

1,840

-273

269

2,214

2,032

3,981

2,236

439

-273

625

-100

-64

734

-145

599

225

-196

421

-212

228

41

-302

-196

-345

114

-691

438

1,952

1,475

2,328

-402

0

0

0

Lease liability

-6,620

-6,725

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-24,302

24,255

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,427

-18,261

-19,335

-19,335

13,427

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and other long term liabilities

0

-

-

-

-

-322

-2,295

-4,239

-6,122

-6,773

-6,276

-5,758

-5,324

-5,294

-5,112

-4,929

-4,750

-5,078

-4,234

-3,394

-2,563

-1,242

-1,096

-959

-823

-688

-553

-419

-283

-150

551

518

484

366

0

0

0

Net cash used in operating activities

-44,034

-41,510

-20,217

-25,658

-36,001

-58,826

-90,185

-87,713

-80,189

-77,557

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-63,820

-

-24,620

-33,540

-35,338

-69,753

-73,651

-76,017

-77,394

-86,077

-88,746

-87,628

-87,047

-85,209

-82,292

-75,460

-71,885

-69,375

0

0

0

Purchases of short-term investments

138,808

145,327

128,439

96,255

92,632

77,996

102,684

113,560

88,711

116,861

84,765

80,078

88,992

103,053

124,404

136,860

149,232

151,763

156,817

176,335

188,934

218,594

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

142,371

123,126

115,406

99,175

94,591

104,066

91,405

93,887

92,926

96,820

101,940

100,281

120,198

128,650

160,856

193,560

178,338

196,862

205,911

201,800

250,950

281,705

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from disposal of assets

-

-

-

-

-

-

-

-

-

732

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

446,229

485,650

543,042

476,038

0

0

0

Maturities of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Maturities and sales of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Capital expenditures

1,685

1,455

913

717

1,286

1,106

1,090

990

320

164

117

313

524

804

932

987

835

546

612

265

267

413

381

549

723

1,221

1,654

1,910

2,479

3,377

2,961

3,138

3,017

2,303

0

0

0

Net cash provided by (used in) investing activities

1,878

-23,656

-13,946

2,203

673

24,964

-12,369

-20,663

3,895

-19,473

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,331

-

48,776

25,434

61,983

62,932

69,515

77,117

57,070

72,396

-59,371

-55,198

-39,433

-39,034

87,073

56,496

-74,454

-62,848

0

0

0

Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan

2,896

1,576

1,981

2,606

2,737

4,732

5,561

5,696

5,178

3,508

2,246

1,790

1,935

1,598

1,566

1,350

1,748

1,761

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale and issuance of common stock, net of offering costs

-

-

-

-

-

-

-

-

-

114,180

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

139,094

3,472

2,478

143,215

142,779

0

0

0

Payments on capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

800

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,040

-

1,607

1,514

1,163

1,170

0

0

0

-

-

-

-

139,094

3,338

2,163

142,666

141,979

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-28,449

-

25,763

-6,592

27,808

-5,651

-3,217

2,014

-19,249

-12,630

-10,770

-4,283

12,126

14,851

8,119

-16,801

-3,673

9,756

0

0

0

Net cash provided by financing activities

12,685

11,365

11,770

2,606

69,899

71,894

138,161

140,863

76,275

117,688

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-29,471

-53,801

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-19

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information
Interest paid

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-